CANCER CENTER ADMINISTRATION - ABSTRACT Administration at the Karmanos Cancer Institute (KCI) provides support to the Cancer Center leadership, Research Program and Shared Resource infrastructure, KCI membership, and staff by providing services aimed at relieving the administrative burden associated with research. Administration contributes to the mission of the Cancer Center by providing efficient management of resources, facilitating key internal and external scientific meetings, strategic planning, and developing useful metrics to aid in the decision making of KCI senior leadership. Mr. Evano Piasentin, Associate Center Director for Research Administration, leads an experienced administrative team. Administration supports 135 scientific members across four research Programs and nine Shared Resources (including one under development). Additionally, Administration manages extramural funding of $63 million (annual direct costs), KCI?s annual research budget of $21 million, and coordinated internal pilot funding of more than $2 million since the last renewal. Notable achievements during the past funding period include a restructuring of the administrative office to capitalize on the unique skills of staff and provide a more efficient and dynamic environment to meet the needs of the Cancer Center. Additionally, Administration supported the planning, process, and development of a new strategic plan through organization of strategic planning retreats convening stakeholders from various disciplines across KCI. The strategic plan is centered on five priority areas: immunology and immunotherapy, cancer metabolism and metabolomics, biology of cancer health disparities, addressing multilevel determinants of risk and survivorship, and increasing interventional research to reduce disparities. Administration continues to implement significant upgrades to the Research Administration Application (RAA), a homegrown repository of CCSG data for KCI. With respect to space management, Administration managed a relocation of basic science laboratories from the outdated Prentis Cancer Research Building to the renovated Elliman Research Building. Finally, Administration played a central role in the development of several large, multi-PI project grants leading to the first-ever funded SPORE grant at KCI; The Michigan Prostate SPORE (P50CA186786).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-39
Application #
10088974
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-08
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
39
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095
Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58

Showing the most recent 10 out of 826 publications